A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients
Not Applicable
Completed
- Conditions
- End-Stage Renal Disease Patients on Hemodialysis
- Registration Number
- NCT00308295
- Lead Sponsor
- Indiana University School of Medicine
- Brief Summary
The main goal of this study is to determine whether the American Heart Association-recommended fish oil dose is efficacious, safe, and tolerable in hemodialysis patients. The secondary objective is to test the effects of fish oil supplementation on inflammatory and cardiovascular markers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Not provided
Exclusion Criteria
- Age <18
- Pregnant individuals
- Fish oil or omega-3 supplementation in past 6 months
- Fish, corn, soybean, gelatin, or vanilla allergies
- Currently enrolled in a dietary or investigational drug study
- Life expectancy < 3 months
- Ongoing active illness requiring hospitalization
- Malabsorption syndromes
- Chronic heparin or coumadin anticoagulation (??)
- Active bleeding issues
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To determine whether AHA-recommended fish oil therapy beneficially affects the pro-inflammatory/anti-inflammatory blood fatty acid balance
- Secondary Outcome Measures
Name Time Method To test the safety and tolerability of fish oil therapy in hemodialysis patients To measure the effects of fish oil treatment on cardiovascular and inflammatory risk factors
Trial Locations
- Locations (2)
VeteransAdministration Hospital
🇺🇸Indianapolis, Indiana, United States
Indiana University Nephrology Clinics
🇺🇸Indianapolis, Indiana, United States